Development of Three Antiretroviral Drugs Halted
Given the effectiveness of current combination ART, it has become increasingly difficult for new drugs to demonstrate superiority to existing therapies in clinical trials.
In July, Merck announced that it was discontinuing development of its investigational CCR5 antagonist vicriviroc for treatment of HIV infection. Last January, the company announced that it would not seek approval of vicriviroc for treatment-experienced individuals. At the 2010 Conference on Retroviruses and Opportunistic Infections (CROI) last February, researchers reported that in the VICTOR trials, vicriviroc did not demonstrate noninferiority to an optimized background regimen plus placebo for this population.View Full Article
Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)